The shortage of essential chemotherapy drugs in the United States
Abstract
Some essential oncology drugs are in short supply in the United States, raising concern about safety, cost, and availability of life-saving treatments. The causes are economic: manufacturers don't make big profits on generics, and oncologists make money on drug markups.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The growing cancer survivor population will strain a healthcare system with frequent cancer drug shortages and oncology demand that is expected to exceed oncologist supply.
“The growing population of cancer survivors will put pressure on a healthcare system in which cancer drug shortages are increasingly common and the demand for oncology services is poised to outpace the supply of oncologists (4–6).”
From Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care (2013) · cites this paper as [6]
Cites
Impact of drug shortages on U.S. health systems.
Kaakeh, R., Sweet, B. V., Reilly, C., Bush, C. G., DeLoach, S. L., Higgins, B., Clark, A. M., & Stevenson, J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110210 · Cited by 230 · see citing works
Neubauer, M., Hoverman, J. R., Kolodziej, M. A., Reisman, L., Gruschkus, S. K., Hoang, S. N., Alva, A. A., McArthur, M., Forsyth, M., Rothermel, T., et al. (2010) · Journal of Oncology Practice · doi:10.1200/jop.091058 · Cited by 172 · see citing works
How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment
Jacobson, M., Earle, C. C., Price, M., & Newhouse, J. P. (2010) · Health Affairs · doi:10.1377/hlthaff.2009.0563 · Cited by 171 · see citing works
Medicare Cost Containment Strategy Targets Several Oncology Drugs
Twombly, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/96.17.1268 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
de Moor, J. S., Mariotto, A. B., Parry, C., Alfano, C. M., Padgett, L., Kent, E. E., Forsythe, L., Scoppa, S., Hachey, M., & Rowland, J. H. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1356 · Cited by 670 · see citing works
Shortages of medicines: a complex global challenge
Gray, A., & Manasse, H. (2012) · Bulletin of the World Health Organization · doi:10.2471/blt.11.101303 · Cited by 136 · see citing works
- Authors
- Gatesman, M. L., & Smith, T. J.
- Affiliations
- Virginia Commonwealth University (US)
- Johns Hopkins University (US)
- ORCID
- Smith, Thomas J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-11-03
- Volume
- 365
- Issue
- 18
- Pages
- 1653-1655
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2130144452
- Cited by
- 122
- References
- 4
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 9 · 2018: 10 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 11 · 2013: 24 · 2012: 22
- FWCI
- 46.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Business, Management and Accounting › Management Information Systems › Supply Chain and Inventory Management
- Keywords
- drug shortages, oncology drugs, generic drugs, drug pricing, pharmaceutical manufacturers, drug availability, drug costs
- MeSH terms
- Antineoplastic Agents, Ethics, Medical, Medicare, Humans, Medical Oncology, Medication Errors, Neoplasms, Reimbursement Mechanisms, United States, Conflict of Interest, Drug Costs, Drugs, Generic, Drugs, Essential
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
